Aurora Spine Corporation

Q2 2024 Earnings Conference Call

8/23/2024

spk02: Good morning, and welcome to the Aurora Spine Second Quarter 2024 Financial Results Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star, then two. Please note, this event is being recorded. I would now like to turn the conference over to Chad Klaus, Chief Financial Officer. Please go ahead.
spk00: Good morning, everyone, and thank you for joining us for Aurora Spine Corporation's quarterly earnings conference call. We look forward to discussing our performance for the second quarter of 2024. Before we dive into the details, I'd like to remind everyone that this call will contain forward-looking statements. These statements involve risk and uncertainties, and actual results could differ materially. For a full discussion of these risk and certainties factors, you are encouraged to read or respond to documents on file with CDAR Plus, including those set forth in periodic reports filed under the forward-looking statements and risk factors section. Statements made during the course of this call may concern forward-looking statements within the meaning of Section 27A of the Security Acts of 1933, as amended and Section 21E of the Securities Act of 1934. These statements reflect current expectations concerning future events and results. Words such as expect, intend, believe, may, will, should, could, anticipate, and similar expressions are words that are used to identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to risk and uncertainty, and other important factors that could cause actual performance or achievements to materially differ from those projected. Rose Spine does not intend to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. On the call, management referred to EBITDA, adjusted EBITDA, adjusted net income, and adjusted EPS. which are not measures of financial performance under generally accepted accounting principles or GAAP. Management believes that these non-GAAP figures, in addition to other GAAP measures, provide meaningful supplemental information regarding the company's operational performance. Investors should recognize that these non-GAAP figures may not be comparable to similarly titled measures of other companies. These measures should be considered in addition to and not as a substitute for superior or any measure of performance prepared in accordance with GAAP A reconciliation of non-GAAP measures and the most directly comparable GAAP measures in accordance with Section or SEC Regulation G can be found in the company's earnings release. We're joined today by Trent Northcutt, our Chief Executive Officer, and myself, Chad Klaus, our Chief Financial Officer. We will present an overview of our financial performance, followed by a Q&A session. I will now turn the call over to Mr. Trent Northcutt, President and Chief Executive Officer of Worth Spine. Trent, please proceed.
spk01: Thank you, Chad. Good morning, everyone. I'm pleased to share our results with the second quarter of 2024, which is our pivotal period for Aurora, with notable progress in both our financial performance, the market penetration, our strategic focus on expanding the sales force and targeting underserved markets has yielded strong results as evidence of our significant sales growth and improved profitability. On Wednesday, we issued a
Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-